E-Mail
IMAGE: UNC Lineberger Comprehensive Cancer Center s Lawrence Marks, MD, and colleagues have published a comprehensive review that highlights the optimal ways that focused, high-dose radiation can be delivered to various types. view more
Credit: UNC Health
CHAPEL HILL, North Carolina A comprehensive review by University of North Carolina researchers and colleagues highlights the optimal ways that focused, high-dose radiation can be delivered to various types of tumors while sparing normal tissue and mitigating long-term side effects. The review was reported as a special issue in the
International Journal of Radiation Oncology, Biology, Physics on May 1, 2021.
This analysis was based on an exhaustive review of data and the literature published largely in the past decade. It updates an earlier review that primarily focused on the effects of conventional radiation therapy on normal tissue. This new review also includes important analyses of how well high-dose ra
Share
The Olympia Morata Programme of Heidelberg University is funding four junior female researchers working on their postdoctoral or comparable qualifications. After a successful review of their applications, Dr Laura Schmidt (psychology), Dr Lisa Baumann (biology), Dr Julia Bauer (medical physics), and Dr Giulia Pelillo-Hestermeyer (Romance studies) have been selected as award recipients. The goal of the university is to increasingly attract women to university and scientific careers.
Dr Laura Schmidt works at the Institute of Psychology in the research unit “health psychology” on health-related behaviour over the entire life span. Her postdoctoral project focuses on practical approaches intended to promote health-related behaviour and well-being through technology-based interventions and psychological techniques on behaviour modification.
PreludeDx PREDICT Study Demonstrates High Clinical Utility of DCISionRT for DCIS Breast Cancer Patients
42% change in treatment recommendations when using DCISionRT
News provided by
Share this article
Share this article
LAGUNA HILLS, Calif., April 21, 2021 /PRNewswire/ Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early stage breast cancer, announced results for a prospective study in 44 U.S. academic and community cancer centers that evaluated the impact of DCISionRT on clinicians recommendations to administer or omit adjuvant radiotherapy (RT) in patients with DCIS (ductal carcinoma in situ) following breast conserving surgery (BCS). Data published today in the
PreludeDx PREDICT Study Demonstrates High Clinical Utility of DCISionRT for DCIS Breast Cancer Patients prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Triple combination therapy shows promise against a rare deadly asbestos cancer eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.